Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Amoroso
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 67
- Beta
- 1.23
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -5.94
Financials
Revenue
$0.00-100.0%Net Income
$-32.65MEBITDA
$-32.10MFree Cash Flow
$-13.52MEPS (diluted)
$-1.26Shares Outstanding (diluted)
25.86M+1200.2%Operating Expenses
$19.16MCash & Debt
$87.55MRevenue by Segment (annual)
$8.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $34.26M | $-45.72M | $-3.56 |
| 2024 | $68.70M | $7.17M | $1.05 |
| 2023 | $48.73M | $-61.32M | $-15.96 |
| 2022 | $25.10M | $-111.64M | $-38.10 |
| 2021 | $115.53M | $-30.60M | $-15.60 |
| 2020 | $24.29M | $-109.01M | $-62.85 |
| 2019 | $22.24M | $-92.88M | $-59.50 |
| 2018 | $10.88M | $-46.04M | $-28.17 |
| 2017 | $6.48M | $-21.10M | $-18.81 |
| 2016 | $7.01M | $-8.25M | $-0.49 |
Valuation
DTILhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsseekingalpha.com·1d ago·Positive
Precision BioSciences: Promising HBV Editing Evidence PBGENE-HBV's liver biopsy data provides unusually direct evidence that ARCUS is editing the viral reservoir in patients. Durable off-treatment viral control remains unproven, making the next ELIMINATE-B updates decisive for the investment thesis. PBGENE-DMD offers a second validation path. However, their program still lacks disclosed human safety or efficacy data.
View source ↗
Earnings
Mon, Nov 2(in 2 months)
Consensus estimate $-0.84 per share
Typical surprise -177.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-1.26 vs $-0.80miss
- Tue, May 5$-0.75 vs $-0.27miss
- Thu, Mar 12$1.05 vs $-0.21beat
- Mon, Nov 3$-1.84 vs $-0.31miss
- Thu, Aug 7$-2.13 vs $-0.09miss
- Thu, May 15$-2.21 vs $-0.43miss
Estimates and results for DTIL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DTIL officers and directors.
- Bought
- $82k
- Sold
- $529k
7 trades
12 trades
- Amoroso Michaelsold
- Kelly John Alexandersold
- Scimeca Dariosold
- Smith J. Jeffersonsold
- Amoroso Michaelsold
- Scimeca Dariosold
- Kelly John Alexandersold
- Smith J. Jeffersonsold
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.